LGALS9 and colitis: On the other hand, findings from HAVCR2 polymorphisms and modulation experiments in autoimmune diseases and IBD, using TIM-3 with blocking antibodies or activation by its ligand galectin-9, rather indicate a predominant inhibitory role, particularly in colitis (Fig. 1) [34, 35, 38, 39, 41].